Fundraising Fox

Steven Elms

Investor

Managing Partner at Aisling Capital · Board director at Treeline Biosciences · Board director at Marker Therapeutics · Board director at Loxo Oncology

United States

Find your path to Steven

29 people in our graph share verified history with Steven — schools, employers, funds. One of them is your warm intro.

David SchenkeinunlockedSteven: together at Treeline Biosciences
×7Steven: together at Aisling Capital
Steven: together at Treeline Biosciences
×3Steven: together at Cidara Therapeutics

About

Elms joined Aisling in 2000 as a Managing Partner. He previously was a Principal in the Life Sciences Investment Banking Group at Chase H&Q and traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. He holds an MBA from Northwestern's Kellogg School and a BA from Stanford.

Likely email· guessed from name + firm domain, not firm-published

Board director at Treeline Biosciences

Intro paths

→

In turn, Steven can intro founders to Treeline Biosciences's investors below.

Treeline Biosciences's investors · 8

Aisling CapitalNew York · since 2025ARCH Venture PartnersChicago · $50K – $250M checks · since 2025Casdin CapitalNew York · since 2025Fidelity InvestmentsBoston · since 2025GV (Google Ventures)Mountain View · $250K – $50M checks · since 2025OrbiMedNew York · $1M – $75M checks · since 2025Rock Springs CapitalBaltimore · since 2025T. Rowe PriceBaltimore · since 2025

Co-founders at Treeline Biosciences

JHJoshua H. Bilenker
Joshua H. BilenkerExecutive Officer, Director, Promoter
JE
Jeffrey EngelmanExecutive Officer, Director, Promoter
JB
Josh BilenkerFounder

Board director at Marker Therapeutics

Intro paths

→

In turn, Steven can intro founders to Marker Therapeutics's investors below.

Marker Therapeutics's investors · 3

Aisling CapitalNew York · since 2024National Institutes of Health (NIH)since 2023New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks

Co-founders at Marker Therapeutics

JVJuan Vera
Juan VeraExecutive Officer, Director
DV
Dr. VeraCo-founder

Board director at Loxo Oncology

Intro paths

→

In turn, Steven can intro founders to Loxo Oncology's investors below.

Loxo Oncology's investors · 2

Aisling CapitalNew York · since 2014New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2014

Co-founders at Loxo Oncology

JH
Joshua H. BilenkerExecutive Officer, Director

Deals · 4

Treeline BiosciencesBoard seat

via Aisling Capital · filed Sep 2025 · $250M raise

Marker TherapeuticsBoard seat

via Aisling Capital · filed Dec 2024 · $16.1M raise

EarlensBoard seat

via Aisling Capital · filed May 2017 · $77.3M raise

LensarBoard seat

via Aisling Capital · filed Jan 2015 · $20M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Aisling Capital

A.J Sacks
Analyst at Aisling Capital
Aftab Kherani
Operating Partner at Aisling Capital
Aftab Kherani
Managing Partner at Ajax Health
Andrew Schiff
Managing Partner at Aisling Capital
Ayman Sabi
Partner at Aisling Capital
Carol Zikopoulos
Head of Human Resources and Compliance Manager at Aisling Capital
Dennis Purcell
Investor at Aisling Capital
Dov Goldstein
Managing Partner at Aisling Capital

Frequently asked questions

Who is Steven Elms?
Elms joined Aisling in 2000 as a Managing Partner. He previously was a Principal in the Life Sciences Investment Banking Group at Chase H&Q and traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. He holds an MBA from Northwestern's Kellogg School and a BA from Stanford.
Where does Steven Elms work?
Steven Elms is Managing Partner at Aisling Capital and Board director at Treeline Biosciences and Board director at Marker Therapeutics and Board director at Loxo Oncology.
What boards does Steven Elms sit on?
Steven Elms holds tracked board seats at Earlens, Lensar, Marker Therapeutics, Treeline Biosciences.